Question: is this a 2) strong advice, 1) weak advice 0) no advice?

Also, given the impressive results obtained with ranibizumab for all types of neovascular AMD, neither PDT nor low-dose TTT should be considered as first-line treatments.
user
This is a strong advice
assistant